Journal Basic Info
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.Major Scope
- Melanoma/Skin Cancer
- Immunotherapy
- Pancreatic Cancer
- Head and Neck Oncology
- Neoadjuvant Therapy
- Radiation Oncology
- Chemoprevention
- Surgical Oncology
Abstract
Citation: Clin Oncol. 2018;3(1):1454.DOI: 10.25107/2474-1663.1454
Increased Risk of Male Breast Cancer with Prolactinoma: A Case Report
Michelle Abghari, Deimante Tamkus and Harvey Bumpers
Departments of Surgery and Medical Oncology, Michigan State University, CHM, USA
*Correspondance to: Harvey Bumpers
PDF Full Text Editorial | Open Access
Abstract:
This case is reported of a 52 year-old male who, seventeen years after the treatment for a prolactinoma and over ten years after the onset of bilateral gynecomastia, developed left sided breast cancer. Ductal carcinoma in situ was found incidentally after he decided to have a left breast mass excised for symptomatic gynecomastia. Pathology reported a 1.0 cm, ductal carcinoma in situ, cribriform, grade 1, estrogen receptor (ER) positive, and progesterone receptor (PR) positive mass which later required a completion mastectomy. The patient was also consequently found to have a decrease in testosterone levels requiring high doses of testosterone replacement therapy. BRCA testing was recommended. In review of the patient’s breast cancer family history, only a paternal aunt was identified. The patient was considered a candidate for contra lateral total mastectomy due to high levels of testosterone replacement and concerns with estrogen conversion. However, genetic testing was found to be negative and endocrine therapy (tamoxifen) was initiated as the patient requested to be treated conservatively.
Keywords:
Male breast cancer; Breast cancer; Prolactinoma
Cite the Article:
Abghari M, Tamkus D, Bumpers H. Increased Risk of Male Breast Cancer with Prolactinoma: A Case Report. Clin Oncol. 2018; 3: 1454.